Variable | Category | All patients (n = 96) | Nm23/NDPK-A positive (n = 73) | Nm23/NDPK-A negative (n = 23) | P value |
---|---|---|---|---|---|
Age | < 65 | 45 (47%) | 32 (44%) | 13 (57%) | 0.2877 |
 | ≥ 65 | 51 (53%) | 41 (56%) | 10 (43%) |  |
Gender | Male | 62 (65%) | 45 (62%) | 17 (74%) | 0.2833 |
 | Female | 34 (35%) | 28 (38%) | 6 (26%) |  |
Location | Head | 73 (76%) | 56 (77%) | 17 (74%) | 0.7839 |
 | Body-Tail | 23 (24%) | 17 (23%) | 6 (26%) |  |
Histological differentiationa | Well | 8 (8%) | 6 (8%) | 2 (9%) | 0.9838 |
 | Moderate + Poor | 77 (80%) | 58 (80%) | 19 (82%) |  |
Tumor stage | T1 + T2 | 10 (10%) | 7 (10%) | 3 (13%) | 0.6363 |
 | T3 + T4 | 86 (90%) | 66 (90%) | 20 (87%) |  |
Nodal stage | N0 | 33 (34%) | 25 (34%) | 8 (35%) | 0.9624 |
 | N1 | 63 (66%) | 48 (66%) | 15 (65%) |  |
NCCNb criteria | Resectable | 50 (52%) | 38 (52%) | 12 (52%) | 0.9920 |
 | Borderline rsectable | 46 (48%) | 35 (48%) | 11 (48%) |  |
Preoperative CA19-9 | < 37 U/mL | 25 (26%) | 17 (23%) | 8 (35%) | 0.2733 |
 | ≥ 37 U/mL | 71 (74%) | 56 (77%) | 15 (65%) |  |
Postoperative CA19-9 | < 37 U/mL | 57 (59%) | 41 (56%) | 16 (70%) | 0.2538 |
 | ≥ 37 U/mL | 39 (41%) | 32 (44%) | 7 (30%) |  |
Adjuvant chemotherapy | Gemcitabine | 58 (60%) | 42 (58%) | 16 (70%) | 0.3035 |
 | Othersc | 38 (40%) | 31 (42%) | 7 (30%) |  |